NovoCure
NVCR
223 hedge funds and large institutions have $1.08B invested in NovoCure in 2026 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 76 increasing their positions, 75 reducing their positions, and 50 closing their positions.
48% more call options, than puts
Call options by funds: $12.2M | Put options by funds: $8.24M
1.6% more ownership
Funds ownership: 85.3% → 86.89% (+1.6%)
1% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 75
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 239 → 223 (-16)
13% less capital invested
Capital invested by funds: $1.24B → $1.08B (-$159M)
24% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$35.1M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$24.5M |
| 3 |
SG Americas Securities
New York
|
+$12.1M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$11.5M |
| 5 |
JP Morgan Chase
New York
|
+$6.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
-$10.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.37M |
| 3 |
Millennium Management
New York
|
-$6.94M |
| 4 |
Morgan Stanley
New York
|
-$6.6M |
| 5 |
Goldman Sachs
New York
|
-$5.4M |
NVCR Hedge Fund Activity: Q1 2026 in Review
223 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q1 2026, worth a combined $1.08B — down 13% from $1.24B a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of NVCR and 38 opened new positions — a net loss of 12 holders — while 75 trimmed existing stakes and 76 added.
The largest buyer was Wells Fargo, adding an estimated $35.1M. The largest seller was American Century Companies, cutting an estimated $10.5M.
- 223 institutional investors held NovoCure (NVCR) as of Q1 2026, down from 239 in Q4 2025.
- Funds reported $1.08B of NovoCure stock for Q1 2026, down 13% quarter-over-quarter.
- 38 funds opened new NovoCure positions in Q1 2026 and 50 closed out, a net change of -12 holders.
- The largest NovoCure buyer in Q1 2026 was Wells Fargo, an estimated $35.1M added.
- The largest NovoCure seller in Q1 2026 was American Century Companies, an estimated $10.5M sold.
Based on aggregated 13F filings for Q1 2026.